Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC) Meeting Abstract
| Authors: | Miksad, R.; Cicin, I.; Chen, Y.; Klumpen, H.; Kim, S.; Lin, Z.; Youkstetter, J.; Sen, S.; Cheng, A.; Meyer, T.; Kelley, R.; Abou-Alfa, G. |
| Abstract Title: | Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC) |
| Meeting Title: | ESMO 21st World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2019 Jul 3-6 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-07-01 |
| Start Page: | mdz154.021 |
| Language: | English |
| ACCESSION: | WOS:000475860200021 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz154.021 |
| Notes: | Meeting Abstract: O-022 -- Appears on page iv134 of the abstract book -- Source: Wos |
